![Jin Hua Hu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jin Hua Hu
Direktor/Vorstandsmitglied bei China Association of Health Education
Profil
Jin Hua Hu is currently the Vice Chairman at China Association of Health Education and a Counselor at Shanghai Municipal People's Congress.
Previously, Mr. Hu worked as an Independent Non-Executive Director at Mingyuan Medicare Development Co. Ltd.
from 2011 to 2014.
Aktive Positionen von Jin Hua Hu
Unternehmen | Position | Beginn |
---|---|---|
Shanghai Municipal People's Congress | Corporate Officer/Principal | 22.03.2010 |
China Association of Health Education | Direktor/Vorstandsmitglied | 15.09.2011 |
Ehemalige bekannte Positionen von Jin Hua Hu
Unternehmen | Position | Ende |
---|---|---|
MINGYUAN MEDICARE DEVELOPMENT CO., LTD. | Direktor/Vorstandsmitglied | 24.04.2014 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Mingyuan Medicare Development Co. Ltd.
![]() Mingyuan Medicare Development Co. Ltd. BiotechnologyHealth Technology Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong. | Health Technology |
Shanghai Municipal People's Congress | Government |
China Association of Health Education |